Cordycepin (3′-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3β activation and cyclin D1 suppression

被引:28
作者
Noriko Yoshikawa
Shizuo Yamada
Chihiro Takeuchi
Satomi Kagota
Kazumasa Shinozuka
Masaru Kunitomo
Kazuki Nakamura
机构
[1] Mukogawa Women’s University,Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences
[2] University of Shizuoka,Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008年 / 377卷
关键词
Adenosine A; receptor; Cordycepin (3′-deoxyadenosine); B16-BL6 mouse melanoma cells; Indirubin; Wnt signaling pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Cordyceps sinensis, a parasitic fungus on the larvae of Lepidoptera, has been used as a traditional Chinese medicine. We previously reported that the growth of B16-BL6 mouse melanoma (B16-BL6) cells was inhibited by cordycepin (3′-deoxyadenosine), an active ingredient of C. sinensis, and its effect was antagonized by MRS1191, a selective adenosine A3 receptor antagonist. In this study, the radioligand binding assay using [125I]-AB-MECA (a selective adenosine A3 receptor agonist) has shown that B16-BL6 cells express adenosine A3 receptors and that cordycepin binds to these receptors. We also confirmed the involvement of adenosine A3 receptors in the action of cordycepin using MRS1523 and MRS1220, specific adenosine A3 receptor antagonists. Next, indirubin, a glycogen synthase kinase-3β (GSK-3β) inhibitor, antagonized the growth suppression induced by cordycepin. Furthermore, the level of cyclin D1 protein in B16-BL6 cells was decreased by cordycepin using Western blot analysis. In conclusion, this study demonstrated that cordycepin inhibits the proliferation of B16-BL6 cells by stimulating adenosine A3 receptors followed by the Wnt signaling pathway, including GSK-3β activation and cyclin D1 inhibition.
引用
收藏
页码:591 / 595
页数:4
相关论文
共 100 条
[1]
Bar-Yehuda S(2005)CF101, an agonist to the A Neoplasia 7 85-90
[2]
Madi L(2006) adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model Mol Cancer Ther 5 685-692
[3]
Silberman D(1950)The antitumor effect of LJ-529, a novel agonist to A Nature 166 949-443
[4]
Gery S(2002) adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers Anticancer Drugs 13 437-552
[5]
Shkapenuk M(2001)Cordycepin, a metabolic product isolated from cultures of Pharmacol Rev 53 527-924
[6]
Fishman P(2005) (Linn.) Biochem Pharmacol 70 918-6423
[7]
Chung H(2003)A Cancer Res 63 6413-42130
[8]
Jung JY(2003) adenosine receptor as a target for cancer therapy J Biol Chem 43 42121-4479
[9]
Cho SD(2004)International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Clin Cancer Res 10 4472-19526
[10]
Hong KA(2005)A novel adenosine analog, thio-Cl-IB-MECA, induces G J Biol Chem 280 19516-142